{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00040586: Phase 2 Interventional Completed Prostatic Neoplasms
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03424603: Phase 1 Interventional Completed B-cell Lymphoma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegloxenatide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04019288: Phase 1/Phase 2 Interventional Completed Platinum-Resistant Fallopian Tube Carcinoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:berlimatoxumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03973515: Phase 1 Interventional Completed Type2 Diabetes Mellitus
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:atidortoxumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:adalimumab fosimdesonide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04478695: Phase 1 Interventional Terminated Relapsed or Refractory Acute Myeloid Leukemia
(2020)
Source URL:
Class:
PROTEIN
